BioMarin to Host Third Quarter 2026 Financial Results Conference Call
BioMarin Pharmaceutical Inc. announced it will hold a conference call and webcast to discuss its third quarter 2026 financial results on November 2, 2026.
Stocks · News reference
Cantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $86 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
BioMarin Pharmaceutical is expected to report Q3 2026 earnings of $1.35 per share (up 1025% YoY) with revenues of $1.03 billion (up 32.7% YoY). The company has a positive Earnings ESP of +9.40% with a Zacks Rank #3 (Hold), suggesting it is likely to beat consensus estimates. BioMarin has beaten EPS estimates in 3 of the last 4 quarters, most recently delivering a +25% surprise.
Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114
Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $111 to $114.